No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BEAM240719C25000
- 0.70
- -0.45-39.13%
15min DelayClose Jun 28 15:59 ET
0.70High0.60Low
0.65Open1.15Pre Close9 Volume134 Open Interest25.00Strike Price580.00Turnover75.84%IV9.69%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.70Extrinsic Value100Contract SizeAmericanOptions Type0.3957Delta0.0934Gamma22.31Leverage Ratio-0.0420Theta0.0044Rho8.83Eff Leverage0.0210Vega
Intraday
- 5D
- Daily
News
Beam Therapeutics(BEAM.US) Officer Sells US$1.47 Million in Common Stock
Beam Therapeutics Insider Sold Shares Worth $1,470,156, According to a Recent SEC Filing
Form 144 | Beam Therapeutics(BEAM.US) Officer Proposes to Sell 1.47 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 27, $Beam Therapeutics(BEAM.US)$ Officer JOHN M EVANS intends to sell 60,000 shares of its common stock on Jun 27, with a total market value of approximately $1.47 million.
Wells Fargo Maintains Beam Therapeutics(BEAM.US) With Buy Rating
Express News | Beam Therapeutics Announced The First Patient Was Treated With BEAM-302, An Investigational In Vivo Base Editing Medicine Designed To Precisely Correct The Underlying Cause Of Severe Alpha-1 Antitrypsin Deficiency, Currently In Phase 1/2 Trial
Express News | Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of Beam-302 in Alpha-1 Antitrypsin Deficiency (Aatd)
Comments
How does the biotech ecosystem support advancements in personalized medicine & genomics? ![]()
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
7
$Beam Therapeutics(BEAM.US$ Will double to 90 dollars 💸 💵 💲
1
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
6
Beam Therapeutics' CEO, John Evans showed confidence in Ms. Shaw's ability to turn scientific innovations into commercial treatments. Shaw recognizes Beam's groundbreaking work in genetic medicine and gene editing, predicting major clinical milestones ahead thanks to the company's comprehensive platform and capabilities.
The first treatment based on CRISPR technology is poised to win FDA approval next month, offering hope to patients and opportunities to investors.
"A turning point in medicine"
Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...
"A turning point in medicine"
Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...
19
2
Read more